MB
RVMD icon

MPM BioImpact’s Revolution Medicines RVMD Stock Holding History

MPM BioImpact’s Portfolio RVMD Stock Details RVMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$92.2M Sell
492,483
-14,293
-3% -$2.09M 5.62% 4
2026
Q1 		$49.3M Buy
506,776
+1,104
+0.2% +$111K 3.81% 7
2025
Q4 		$40.3M Buy
505,672
+189,950
+60% +$12.5M 4.61% 6
2025
Q3 		$14.7M Hold
315,722
– – 2.41% 19
2025
Q2 		$11.6M Sell
315,722
-1,361
-0.4% -$52.3K 2.01% 22
2025
Q1 		$11.2M Buy
317,083
+3,266
+1% +$133K 1.93% 19
2024
Q4 		$13.7M Buy
313,817
+22,426
+8% +$1.13M 1.95% 20
2024
Q3 		$13.2M Buy
291,391
+1,995
+0.7% +$86.9K 1.98% 19
2024
Q2 		$11.2M Buy
289,396
+16,179
+6% +$605K 1.75% 19
2024
Q1 		$8.81M Sell
273,217
-191
-0.1% -$5.66K 1.42% 27
2023
Q4 		$7.84M Hold
273,408
– – 1.83% 24
2023
Q3 		$7.57M Hold
273,408
– – 2.02% 18
2023
Q2 		$7.31M Buy
273,408
+26,386
+11% +$647K 1.47% 20
2023
Q1 		$5.35M Buy
247,022
+97,979
+66% +$2.41M 1.39% 20
2022
Q4 		$3.55M Buy
149,043
+3,002
+2% +$63.8K 0.92% 23
2022
Q3 		$2.88M Hold
146,041
– – 0.68% 28
2022
Q2 		$2.85M Hold
146,041
– – 0.79% 28
2022
Q1 		$3.73M Hold
146,041
– – 1% 28
2021
Q4 		$3.68M Sell
146,041
-3,959
-3% -$112K 0.67% 28
2021
Q3 		$4.13M Buy
+150,000
New +$4.37M 0.64% 29

Other funds holding RVMD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

MPM BioImpact's RVMD Position: Q2 2026 in Review

MPM BioImpact reduced its Revolution Medicines (RVMD) stake by 2.8% in Q2 2026, selling an estimated $2.09M and leaving 492,483 shares worth $92.2M. The position accounts for 5.62% of the portfolio, ranked #4.

MPM BioImpact first reported a position in RVMD in Q3 2021 and has held it in 20 quarters since. 693 funds tracked by Wall St. Rank hold RVMD as of Q2 2026.

  • MPM BioImpact held 492,483 shares of Revolution Medicines worth $92.2M as of Q2 2026.
  • MPM BioImpact sold 14,293 Revolution Medicines shares in Q2 2026, an estimated $2.09M.
  • Revolution Medicines made up 5.62% of MPM BioImpact's portfolio in Q2 2026, its #4 holding.
  • MPM BioImpact first reported a position in Revolution Medicines in Q3 2021 and has held it in 20 quarters since.
  • 693 funds tracked by Wall St. Rank held Revolution Medicines as of Q2 2026.

Based on MPM BioImpact's 13F filing for Q2 2026, filed 14 Aug 2026.